Neurosteer Business
Product stage
Clinical Trial
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringMedical DevicesMedical MonitorsDiagnostics Devices
Target Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticals
Core Technology
Artificial IntelligenceMachine LearningData StorageCloudSemiconductors & ElectronicsWearablesSensing
Tags (28)
diagnosticsneurologymonitoringdigital-healthcaresignal-processingalzheimers-diseasesensorshospitalshealthcare-providersemotions-analyticsepilepsydata-analyticsbig-datapatientsnon-invasiveartificial-intelligencewearableneurosciencemachine-learningmedical-devicescloud-basedpharma-companiesearly-detectionbiomarkerswellnesshome-carebrain-disorderremote-monitoring
Neurosteer Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
Neurosteer Lifecycle
Cumulative Funding Raised Over Time
Neurosteer News
4 articles
Neurosteer pursues wearable device to detect Alzheimer's
Israeli company Neurosteer, founded by CEO Nathan Intrator, has developed a wearable device that can remotely evaluate patients for their risk of developing neurodegenerative diseases such as Alzheimers disease, Parkinsons disease, and frontotemporal dementia. The device consists of a three-electrode strip that is placed on the patients forehead and uses signal processing, artificial intelligence, and machine learning to produce biomarkers linked to brain states and neurological disorders. Neurosteer is currently conducting clinical trials in multiple countries and hopes to obtain FDA approval for its device in 2020. The company has received over $5 million in investments from individuals with personal connections to neurodegenerative disorders. The device is expected to have a positive impact on the companys growth.
CustomersInvestment
New monitoring tool could revolutionize brain treatment
Neurosteer, an Israeli company, has developed the worlds first miniature, wearable continuous brain-activity monitor. The device, currently in clinical trials, offers a more user-friendly alternative to traditional EEG and fMRI exams. It is inexpensive, portable, and can be used on a 24/7 basis. The device wirelessly transmits sensor data to a cloud-based server, allowing for continuous brain monitoring and analysis. Neurosteer is expected to receive FDA approval this year for neurodegenerative or epilepsy monitoring. The device has the potential to be used for initial assessment of neurological disorders, as well as in drug development and discovery. Neurosteer has raised approximately $5 million in funding and is seeking partners to develop additional applications for its technology.
CustomersInvestment
Cracking the Code on Mobile Brain Monitoring -Nathan Intrator, Neurosteer-Full
Nathan Intrator, founder of Neurosteer and professor of computer science, discusses the progress his company has made in the development of new applications for brain monitoring. Intrator believes that home monitoring will have a significant impact on patients and the general population, and that Israel’s evolving digital health ecosystem is playing a key role in this progress. He also talks about the potential for brain monitoring in the gaming industry, and the intersection of brain monitoring with virtual and augmented reality.
Expand
Neurosteer: introducing a novel brain activity monitor
Neurosteer Team
Prof. Nathan Intrator
Founder
Founder
Gil Shoshan
Algorithm Engineer
Lior Molcho
Clinical Trials Manager
Neta Maimon
Director Musical Cognition
Danny Gross
Senior Software Architect
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 19 classification IDs that could be used for matching.